Kornimate/medical-research-clean huggingface dataset:
t-cell responses to concurrent hiv and herpesvirus infections

Conditions: HIV; HIV Infections

Summary: this is a research study in which we are trying to discover new information about how hiv and herpes viruses interact with the immune system. the goal of the study is to learn more about how t-cells in your immune system respond to and fight off long-term (chronic) viruses, in order to improve medical care in the future.

hiv-uninfected \& hiv-infected participants who enroll on this study will be asked to provide blood samples for 18 months. these samples will be used to assess t-cell responses and presence of herpesvirus(es). primary objective characterize phenotypic and functional features, including tcr repertoires of hiv-specific cd8 t-cell responses and exhaustion in hiv-positive humans with and without concomitant herpesvirus infections.

Eligibility criteria:
inclusion criteria: * criteria • participant is greater than or equal to 18 years of age. group 1 (hiv uninfected) only * participant is hiv negative per antibody screen conducted on premises * participant is enrolled on hptn 083 study (receiving hiv-prep) (see recruitment and screening). group 2 (hiv infected) only * participant has initiated art therapy as a patient at st jude children's research hospital \*note: participants will be allowed to continue on study and have data analyzed regardless of presence of detectable hiv or cd4+ counts. a) newly diagnosed hiv * participant is hiv-1 positive per medical record documentation or positive antibody screen conducted on premises, with initial diagnosis within 90 days prior to enrollment b) prolonged hiv * participant is hiv-1 positive per medical record documentation or positive antibody screen conducted on premises, with initial diagnosis more than 365 days prior to enrollment exclusion criteria: * participant is unable or unwilling to provide informed consent. * if female of child bearing potential, participant has a positive urine pregnancy test at screening. note: if participant becomes pregnant while on study, they may not continue on study. * concurrent enrollment on a research study or receiving treatment for concurrent medical diagnosis with any of the following interventions which may impact study outcomes: high dose or prolonged steroids, chemotherapy to treat malignancy, radiation therapy, biologic pharmaceutical treatments that induce immunosuppression. * if in the opinion of the investigator, participation in the blood draw would endanger the health of the participant. * participant is enrolled in other clinical trials that include any blood sampling such that the cumulative blood draws would exceed that established as constituting minimal risk (e.g., more than 550 ml in an 8 week period with collection more frequently than 2 times per week).
correlation between dehydroepiandrosterone sulfate and sebum level in adult female acne vulgaris

Conditions: Acne Vulgaris; Female

Summary: the aim of this study is to determine the correlation between dehydroepiandrosterone sulfate (dheas) and sebum level in adult female acne. a cross sectional study was conducted with 50 samples, in june to october 2017.

epidemiological studies have shown that number of adult female acne vulgaris (av) increases. hormone, sebum production, propionibacterium acne and inflammatory process are factors involved in av development. the aim of this study is to determine the correlation between dehydroepiandrosterone sulfate (dheas) and sebum level in adult female acne. this research used cross sectional study with 50 samples, aged 25-49 years by consecutive sampling. the degree of acne vulgaris was evaluated using lehman criteria , and then the sebum level and dheas were measured objectively using sebumeter and serum, respectively.

Eligibility criteria:
inclusion criteria: * female, age 25-29 years * diagnosed with mild to severe acne vulgaris * agree to participate exclusion criteria: * history of taking antiandrogen drugs * history of taking oral and topical antibiotics, using topical retinoid and bpo in the last 4 weeks * history of taking oral isotretinoin in the last 6 months * pregnancy or breastfeeding

Keywords: acne vulgaris sebum level dehydroepiandrosterone sulfate
investigation on the value of bilateral index (bis) monitoring for magnetic seizure versus electroconvulsive therapy

Conditions: Depression

Summary: electroconvulsive therapy (ect) has been shown to be an effective treatment for patients suffering from depression, who do not respond to medical treatment. however it is often dismissed by patients, who feel uncomfortably about the application of electric shocks to their heads. in 2000, magnetic seizure therapy (mst) has been introduced which uses magnetism instead of electricity to evoke convulsions. mst seems to be as effective as ect in terms of its antidepressant potency but may be associated with less severe cognitive side effects. control of anaesthesia during seizure therapy is demanding since light anesthesia might be associated with awareness, whereas deep anesthesia impedes the antidepressant effect of the convulsion. therefore, bispectral index (bis) monitoring is frequently used to tailor anaesthesia for ect, however little is known about bis following mst. the investigators hypothesize that in comparing mst with ect, (a) patients show a faster increase in bis and that (b)less left-right differences occur in bis.


Eligibility criteria:
inclusion criteria: * depression exclusion criteria: * age \< 18 years old * pregnancy

Keywords: depression bispectral index electroconvulsive therapy magnetic seizure therapy
incidence, risk factors, and risk model of acute kidney injury after thoracic aortic surgery

Conditions: Thoracic Aortic Surgery

Summary: postoperative acute kidney injury (aki) is still one of the serious complications of thoracic aortic surgery, with incidence of 8 to 50 percent. postoperative aki significantly increases the morbidity and mortality of patients undergoing thoracic aortic surgery. previous studies for aki after dhca reported confounding results due to different criteria of aki. therefore, the investigators tried to evaluate the incidence and risk factors of aki after thoracic aortic surgery according to the diagnostic criteria and staging system of aki reported from acute kidney injury network. the investigators also tried to develop a risk model with scoring system of aki and evaluate the performance of the risk model.

significant improvement of morbidity and mortality has been achieved during last three decades since developing deep hypothermic circulatory arrest (dhca). however,postoperative acute kidney injury (aki) is still one of the serious complications of thoracic aortic surgery, with incidence of 8 to 50 percent. postoperative aki significantly increases the morbidity and mortality of patients undergoing thoracic aortic surgery. previous studies for aki after dhca reported confounding results due to different criteria of aki. therefore, the investigators tried to evaluate the incidence and risk factors of aki after thoracic aortic surgery according to the diagnostic criteria and staging system of aki reported from acute kidney injury network (2007). the investigators also tried to develop a risk model with scoring system of aki and evaluate the performance of the risk model.

Eligibility criteria:
inclusion criteria: * patients who underwent thoracic aortic surgery during 1994 to 2010 period exclusion criteria: * patients who had previous renal failure before aortic surgery

Keywords: thoracic aortic surgery acute kidney injury
post market clinical follow-up study for the amvia/solvia pacemaker family

Conditions: Bradycardia; Heart Failure

Summary: the study is designed as an open-label, prospective, international, multicenter, non-randomized study to determine safety and product performance of the ce-marked amvia/solvia pacemaker family, including the aatp, crt autoadapt and early check features in the setting of a post-market clinical follow-up study.


Eligibility criteria:
inclusion criteria: * standard indication for de novo, upgrade or replacement pacemaker or cardiac resynchronization therapy pacemaker (crt-p) implantation * ability to understand the nature of the study * willingness to provide written informed consent * ability and willingness to perform all follow-up visits at the study site * ability and willingness to use the cardiomessenger and acceptance of the biotronik home monitoring® concept exclusion criteria: * planned for conduction system pacing * planned cardiac surgical procedures or interventional measures other than the study procedure within the next 12 months * known pregnancy or breast feeding * age less than 18 years * participation in another interventional clinical investigation * life-expectancy less than 12 months
carbohydrate content in the diet in type 1 diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: the aim of this study is to analyse the effect of a diet with a moderate amount of carbohydrates and compare it with a traditional diabetic diet with a higher content of carbohydrates on mean glucose level, high and low glucose levels, and the risk of ketoacidosis in patients with type 1 diabetes. the glucose levels will be measured by blinded continuous glucose monitoring (cgm). the trial has a cross-over design and 12 weeks in duration, where patients will be randomized to; 1) a diet with moderate carbohydrate content for 4 weeks and 2) a traditional diabetes diet for 4 weeks and with a wash-out period between for 4 weeks. the two diets will both be healthy and planned by a dietitian. there will be 50 subjects included in the study.


Eligibility criteria:
inclusion criteria: * type 1 diabetes * adults 18 years or older * written informed consent * hba1c ≥ 58 mmol/mol (7,5 % dcct standard) exclusion criteria: * pregnancy or planned pregnancy for the study duration * severe cognitive dysfunction or other disease, which is judged by the physician to be not suitable for inclusion * problems with compliance to the intervention diets (excluding a lot of the foods that are common in the diets like wholegrain/beans/lentils/fruit/vegetables) because of personal preferences, other diseases, stomach problems etc. * diabetes duration \< 1 year * planned change in diabetes treatment (eg. start with insulin pump, cgm etc.) during the study period * other investigator-determined criteria unsuitable for patient participation

Keywords: carbohydrates diet diabetes mellitus, type 1
adipocyte function and somtropin deficiency

Conditions: Growth Hormone Deficiency

Summary: to assess the influence of exogenous gh (growth hormone) administration on adipocyte endocrine function (leptin, adiponectin, and resistin) and on ghrelin secretion in children with delayed growth due to gh deficiency. study hypothesis: hormones produced by the adipocyte (leptin, adiponectin, and resistin) and ghrelin may exert a certain control on production of gh and igf-i, and gh may in turn have a regulatory effect on such hormones.


Eligibility criteria:
inclusion criteria: * children of both sexes aged from 5 to 12 years, tanner stage 1, with no signs of imminent pubertal development. amenable to treatment with recombinant somatropin in the approved indication of low growth due to gh deficiency * selection of recombinant somatropin by the physician in the treatment authorization request, and subsequent approval of such treatment by the relevant growth hormone committee * body mass index (bmi) within ±1 sd exclusion criteria: * children with any of the reported contraindications for treatment with recombinant somatropin, existence of active neoplasms, progression or recurrence of intracranial lesion, etc. will not be studied * diabetes mellitus * intestinal inflammatory disease * celiac disease * uncontrolled hyperthyroidism * aids * other diseases causing chronic malabsorption, hypercatabolism or malnutrition conditions * chronic liver disease * eating disorders: anorexia, bulimia, etc * long-term treatment with anti-obesity drugs or drugs causing malabsorption
effects of chronic use of doxazosin in men with benign prostatic hyperplasia

Conditions: Benign Prostatic Hyperplasia

Summary: in this study, we investigate the changes of the expression of alpha adrenergic receptor in the prostate tissue during 2-yr medication period in the man with benign prostatic hyperplasia. and we also evaluate the efficacy and safety of 24 mo-treatment with doxazosin (4mg, 8mg)

to compare the expression of alpha-1 adrenergic receptors, we will use various methodologies such as * real-time rt-pcr * radioligand receptor binding * western blot * immunohistochemistry

Eligibility criteria:
inclusion criteria: * 50 yrs or greater * international prostatic symptom score \>= 8 * maximal flow rate \< 15ml/sec * baseline psa 2.5-10 ng/ml * pathologically proven bph * no medication history for bph * able to give fully informed consent exclusion criteria: * previous use of alpha-blocker, 5-alpha reductase inhibitor * previous surgery for bph * urologic cancer history * urethral stricture * baseline psa \> 10ng/ml * bp \< 90/70 mmhg * orthotopic hypotension with syncope * serum cr \> 2.0 mg/dl, alanine aminotransferase \> 1.5 times of normal limit * bacterial prostatitis within 1 year * urinary tract infection(uti) more than 2 times within 1 year * active uti or prostate biopsy within 1 month * unable to void * ped use because of incontinence * hypersensitivity to alpha-blocker that include quinazoline * unstable angina, myocardial infarction, or cerebrovascular accident within 6 months * neurogenic bladder dysfunction (ex. multiple sclerosis, parkinson's disease, spinal injury etc.) * psychiatric problem * alcohol abuse or other drug abuse history * severe comorbidities unable to perform long-term trial * seems not to be appropriate to this study because of any other reasons

Keywords: benign prostatic hyperplasia alpha adrenergic blockers alpha-1 adrenergic receptor
aberrant dna methylation to predict metachronous gastric neoplasms

Conditions: Metachronous Neoplasm; Gastric Cancer; Gastric Neoplasm; Aberrant DNA Methylation

Summary: the study is a prospective cohort study to investigate whether aberrant dna methylation can be useful for the prediction of metachronous recurrence after endoscopic resection of gastric neoplasms (dysplasia or cancer). from 2012 to 2017, 300 patients were prospectively enrolled after endoscopic resection (er) of gastric dysplasia or early gastric cancer. all lesions were assessed by endoscopy and biopsy before er. endoscopic mucosal resection (emr) or endoscopic submucosal dissection (esd) was performed for gastric dysplasia and early gastric cancers which met the absolute indication (differentiated adenocarcinoma, intramucosal cancer, lesions \ 1 year after initial diagnosis.


Eligibility criteria:
inclusion criteria: * patients who underwent endoscopic resection of gastric neoplasms (dysplasia or early gastric cancer) * all gastric neoplasms at diagnosis should be curatively resected before enrollment. exclusion criteria: * previous history of all cancers. * previous history of gastrectomy * non-curative resection of gastric neoplasms * refusal to consent
the post-operative analgesia of the virtual reality using a mirror therapy after total knee arthroplasty

Conditions: Osteoarthritis, Knee; Nociceptive Pain; Virtual Reality

Summary: it was well known that the mirror therapy could decrease pain of upper-limb amputated patients. the mirror therapy is known to make a plastic change some parts of the brain perceiving the painful body part and modulating its signal by feedback of visual information mirrored with the corresponding contra-lateral normal parts. in this study, post-operative analgesic efficiency of the virtual reality using a mirror therapy after total knee arthroplasty will be evaluated. this clinical trial will be performed in the form of prospective, single-blind (i.e. assessor-blind), parallel group, randomized (allocation ratio 1:1), single cohort.


Eligibility criteria:
inclusion criteria: * patients who were transferred to rm after unilateral tka exclusion criteria: * patients cannot freely move the contralat. leg d/t neurologic or musculoskeletal problems * patients are not enough clear to indicate vas * patients cannot look at the virtual reality monitor d/t visual problem * refusal of the participation
thumb and wrist proprioception exercises.

Conditions: Radius Fractures; Hand Injuries; Pain, Chronic; Proprioceptive Disorders

Summary: distal radius fracture is the most common upper extremity fracture with peak incidence among older women after the fifth decade of life. proprioception is one constituent of a complex sensory motor control process. proprioception requires the reception and central integration of incoming afferent signals. although various sensory and motor deficits have been correlated with significant functional impairment after wrist trauma, limited research exists on the effects of proprioception and multi sensory training after distal radius fracture.

a randomized, controlled, single-center, double-blind, clinical trial, with 1:1 allocation ratio, will be carried out involving patients diagnosis of distal radius fracture (aged 18 years and above). both assessor and statistician will remained blinded. standard rehabilitation program for distal radius fracture treatments will received for both the control and experimental groups for a period of 12 weeks. the experimental group, in addition, will received a proprioceptive training program during the same intervention period, which will be conducted twice weekly (24 sessions). the severity of pain with activity will be measured according to the visual analog scale (vas). prwe questionnaire will be used to measure upper extremity function. patient's occupational performance will be measured with the canadian occupational performance measure (copm) and proprioception with joint position sense (jps) and force sense (fs) testing, for dexterity due pegboard test will be used. all outcome measures will be collected at baseline, immediately following the intervention at 3 weeks and at 12 weeks following the end of the intervention. participation in the study will be voluntary and patients will be included if they satisfied specific inclusion criteria. all procedures will be follow in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the helsinki declaration. all participants will sign a written informed consent in accordance with guidelines approved by the local ethics committee.

Eligibility criteria:
inclusion criteria: * patient diagnosis of distal radius fracture. * wrist immobilization after lesion (unless 3 weeks) * capacity for sing inform concept and understand the exercises exclusion criteria: * others associate fractures in hand or upper limb * wrist ligaments injuries * neurological disorder affecting the upper limb * have received previous proprioceptive training for upper limb injury.
community based management of fast breathing in infants aged < 60 days in low-income settlements of karachi

Conditions: Fast Breathing in Young Infants

Summary: the aim of the study is to determine optimal management of isolated fast breathing in young infants in a trial design conducted in primary care settings. the investigators hypothesized that proportion of infants who fail therapy will be 4% in each group. a 6% or less difference in failure rate will be considered equivalent.

the management of isolated fast breathing is therefore unknown and our experience suggests that these infants could perhaps be managed without antibiotics. widespread application of the who clinical algorithm could therefore result in the referral of as many as 13.7% (135.7 per 1000 live births) of all infants for isolated fast breathing, the vast majority of these unnecessarily, and exposing infants to a high risk of nosocomial sepsis and hospital mortality in addition to over-burdening health resources.

Eligibility criteria:
inclusion criteria * young infant (0-59 days of age) * fast breathing i.e., respiratory rate ≥60 breaths/min * o2 saturation ≥90% * resident of catchment area (to ensure complaint and follow up) * refused hospitalization and investigations * informed consent is provided by a parent (or legal guardian). exclusion criteria: * preterm infants (born \<37 weeks) * presence of audible murmur * any concurrent signs of severe infection: * not feeding well * movement only when stimulated * severe chest in-drawing * axillary temperature ≥38.0oc or ≤35.5oc * any sign of being critically ill (cyanosis, bulging fontanel, unable to feed, unable to cry, apnoea, convulsions, unconscious, persistent vomiting) * weight \<1800gm at the time of presentation * major congenital malformations or suspected chromosomal abnormalities * hospitalization for illness in the last two weeks * previous inclusion in the study

Keywords: fast breathing young infants management amoxicillin placebo
trends of patient-reported outcome measures (proms) in multimorbid medical patients hospitalized for an acute illness

Conditions: PROM; PREM; Quality of Care; Internal Medicine

Summary: currently, proms and prems are not routinely collected and compared among medical inpatients of swiss university hospitals, nor is a standard set of proms and prems available for use in swiss hospitals. the project aims to examine trends in patient-reported outcomes (proms), including symptoms, quality of life, and distress, in multimorbid hospitalized patients from admission to 30 days post-discharge. it will also investigate whether proms at discharge are linked to the risk of readmission or emergency visits and explore how these outcomes differ in patients who receive low-value care. additionally, the project will assess the relationship between patient-reported experiences (prems) and the provision of low-value care during the hospital stay.


Eligibility criteria:
inclusion criteria: * eligible for the lucid registry (cer-vd ao_2023-00029) \[age ≥ 18 years, hospitalized in one of the five participating university hospitals (geneva, lausanne, bern, zürich, basel), after 01.01.2014, and admitted to general internal medicine wards * multimorbid patients (2 or more chronic diseases, defined as chronic conditions defined by international classification of diseases, 10th revision, codes with an estimated expected duration of at least 6 months or based on a clinical decision. * acute illness * signature of study specific informed consent exclusion criteria: * not able to speak french, german or english * foreseen length of stay of less than 4 days (estimated by study collaborators) * prior inclusion in the traduce study * incapacity of discernment, i.e. cognitive impairment which could interfere with the ability to fill in proms tools
evaluate the safety and anti-hypertensive efficacy of hyzaar(r) in patients with mild to moderate essential hypertension (0954a-323)

Conditions: Hypertension

Summary: evaluate the safety and anti-hypertensive efficacy of hyzaar(r) in patients with mild to moderate essential hypertension.


Eligibility criteria:
inclusion criteria: * patient is either receiving high blood pressure monotherapy or no treatment * patient will have reached the legal age by the time enter the study * patients diagnosed with mild to moderate essential high blood pressure or high blood pressure with other conditions such as diabetes or cardiovascular diseases and are taking high blood pressure medication (exclude diuretic), but did not meet treatment goal exclusion criteria: * patient with high levels of uric acid in the blood who has received medications for uric acid in the urine within 3 months prior to enrollment * patients who are hypersensitive to any component of the study medication * patients who are hypersensitive to other sulfonamide-derived drugs * patients with anuria (hyzaar(r) is not recommended for patients with hepatic impairment or severe renal impairment, creatinine clearance \</= 30 ml/min) * unstable diabetes (hba1c \> 8%), or a change in diabetes medication during study treatment. patients with stable diabetes may enter the study.